Form 4: Cocrystal Pharma Co-CEO and CFO James Martin Reports Acquisition and Disposal of Common Stock

James Martin, Co-CEO and CFO of Cocrystal Pharma, reports acquiring 40,000 shares of common stock and disposing of 40,569 shares through restricted stock units.

Summary

• On October 9, 2024, James Martin, the Co-CEO and CFO of Cocrystal Pharma, reported a transaction involving the company's common stock.
• Martin acquired 40,000 shares of common stock through restricted stock units (RSUs).
• He also disposed of 40,569 shares.
• Following these transactions, Martin still beneficially owns 40,569 shares.
• The RSUs vest in installments, with half already vested and the remainder vesting quarterly until September 30, 2025, contingent upon continued service.
• The RSUs will fully vest upon a Change of Control as defined in the company's 2015 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The remaining RSUs will vest in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the stock ownership of a key executive.

Key Dates